Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 11/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22414112 | 1.00 | CYP2A6 (0.54) | CYP2A6NAMPTCYP3A4CYP2C9CYP2D6 | |
| SCHEMBL27389563 | 1.00 | CYP2A6 (0.54) | CYP2A6NAMPTCYP3A4CYP2C9CYP2D6 | |
| SCHEMBL30455599 | 1.00 | CYP2A6 (0.54) | CYP2A6NAMPTCYP3A4CYP2C9CYP2D6 | |
| SCHEMBL16019160 | 0.85 | CYP2A6 (0.56) | CYP2A6NAMPTCYP3A4CYP2C9CYP2D6 | |
| SCHEMBL1207728 | 0.85 | CYP2A6 (0.56) | CYP2A6NAMPTCYP3A4CYP2C9CYP2D6 | |
| SCHEMBL15689373 | 0.85 | CYP2A6 (0.56) | CYP2A6NAMPTCYP3A4CYP2C9CYP2D6 | |
| SCHEMBL29527412 | 0.85 | CYP2A6 (0.56) | CYP2A6NAMPTCYP3A4CYP2C9CYP2D6 | |
| SCHEMBL15698999 | 0.85 | CYP2A6 (0.56) | CYP2A6NAMPTCYP3A4CYP2C9CYP2D6 | |
| SCHEMBL15689662 | 0.85 | CYP2A6 (0.56) | CYP2A6NAMPTCYP3A4CYP2C9CYP2D6 | |
| SCHEMBL14708963 | 0.85 | CYP2A6 (0.56) | CYP2A6NAMPTCYP3A4CYP2C9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034725-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200283478-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2020-09-10 | — | — | US | disclosed |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283478-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | PCSK9, PCSK7, PCSK6 | CYP2A6 2648/4885NAMPT 538/4885CYP3A4 3635/4885 |
| US-11034725-B2 | Compositions and methods for treating cardiovascular disease | PCSK9, PCSK7, PCSK6 | CYP2A6 2648/4885NAMPT 538/4885CYP3A4 3635/4885 |
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | PCSK9, PCSK7, PCSK6 | CYP2A6 2648/4885NAMPT 538/4885CYP3A4 3635/4885 |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | PCSK9, PCSK7, PCSK6 | CYP2A6 2648/4885NAMPT 538/4885CYP3A4 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.